Samarth Kulkarni Sells 9,798 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,798 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total value of $517,334.40. Following the completion of the sale, the chief executive officer owned 235,558 shares of the company’s stock, valued at approximately $12,437,462.40. This trade represents a 3.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Samarth Kulkarni also recently made the following trade(s):

• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $52.58, for a total value of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total value of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Stock Down 2.1%

Shares of CRSP traded down $1.06 during trading on Thursday, reaching $48.87. The company’s stock had a trading volume of 3,284,940 shares, compared to its average volume of 1,997,127. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The company has a market cap of $4.69 billion, a price-to-earnings ratio of -7.50 and a beta of 1.72. The company has a fifty day moving average of $54.27 and a two-hundred day moving average of $57.34.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company’s revenue was down 97.8% on a year-over-year basis. During the same period in the prior year, the company earned ($1.01) earnings per share. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Mcguire Capital Advisors Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $25,000. Ramirez Asset Management Inc. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $26,000. Optiver Holding B.V. boosted its position in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares during the last quarter. Thompson Investment Management Inc. bought a new position in CRISPR Therapeutics in the 3rd quarter valued at $33,000. Finally, Strategic Advocates LLC purchased a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at $34,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Bank of America cut their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Morgan Stanley restated an “underweight” rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $64.24.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY2025 commercial progress — CRSP reported growth in commercial revenue driven by CASGEVY (reported $116M for FY25, $54M in Q4), which supports the long‑term commercial thesis for the company’s lead product. CRSP FY25 revenue
• Positive Sentiment: Institutional interest — reports show notable additions by some funds (including ARK Invest) in recent quarters, a sign that selective investors see upside at current levels. This can provide a backstop for shares over time. ARK buys
• Neutral Sentiment: Analyst model tweaks — Brookline Capital made small downward tweaks to FY2028–FY2030 EPS forecasts (minor reductions in multi‑year projections). These adjustments are modest and reflect model updates rather than new negative clinical data. (Source: Brookline reports)
• Neutral Sentiment: Short‑interest data appears anomalous — filings in mid‑March show zero reported short interest in the dataset provided, a likely reporting artifact; days‑to‑cover is effectively 0.0 in those numbers, so this item offers no clear directional signal. (Data summary)
• Negative Sentiment: Upsized $550M convertible senior notes offering — CRSP priced $550M of convertible notes due 2031 (upsized from $350M) with an initial conversion price ~ $76.56 (≈45% premium to pre‑deal price). While proceeds (~$536M net) bolster liquidity, the deal introduces potential future dilution if conversions occur and the upsizing/offer timing likely pressured the share price today. Convertible notes PR
• Negative Sentiment: Near‑term market reaction — news flow around the financing and profit taking led to a sharp intraday decline in recent sessions, reinforcing that the convertible deal + analyst updates are the primary drivers of today’s weakness. Market dip

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.